DUX4 and Facioscapulohumeral dystrophy: DUX4 and DUX4 target candidates’ expression were both repressed following treatment with β2 adrenergic receptor agonists, suggesting the role of BET and β2 adrenergic receptor signalling pathways in DUX4 expression in FSHD patients [51].